<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807026</url>
  </required_header>
  <id_info>
    <org_study_id>15107</org_study_id>
    <secondary_id>I4O-EW-BACX</secondary_id>
    <nct_id>NCT01807026</nct_id>
  </id_info>
  <brief_title>A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease</brief_title>
  <official_title>A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done for the following reasons:

      To determine the safety of LY2886721 and any side effects that may be associated with it and
      to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one
      dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It
      will also look at how safe and tolerable the study drug is when given to healthy participants
      in higher doses.

      This research study is being conducted in three groups, referred to as Groups (Cohorts) A, B,
      or C.

      Group A will enroll participants with Alzheimer's disease while Groups B and C will enroll
      healthy participants.

      For Group A or B, participation in this research study could last up to 34 days. For Group C,
      participation could last up to 60 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721</measure>
    <time_frame>Predose through 96 hours after administration of study drug</time_frame>
    <description>AUC0-∞ following administration of a single dose of 70 or 280 mg LY2886721.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721</measure>
    <time_frame>Predose through 96 hours after administration of study drug</time_frame>
    <description>Cmax following administration of a single dose of 70 or 280 mg LY2886721.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721</measure>
    <time_frame>Predose through 36 hours after administration of study drug</time_frame>
    <description>AUC0-∞ following administration of a single dose of 70 mg LY2886721.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721</measure>
    <time_frame>Predose through 36 hours after administration of study drug</time_frame>
    <description>Cmax following administration of a single dose of 70 mg LY2886721.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40</measure>
    <time_frame>Predose, up to 96 hours after administration of study drug</time_frame>
    <description>Plasma concentration of Aβ1-40 was summarized based on lowest observed concentration (Cnadir).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD: Cnadir of CSF Aβ 1-40</measure>
    <time_frame>Predose up to 36 hours after administration of study drug</time_frame>
    <description>Plasma concentration of Aβ1-40 was summarized based on Cnadir following administration of a single dose of 70 mg LY2886721 or a single dose of LY2886721-matching placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort C: Mean QTcF Value at Cmax</measure>
    <time_frame>Predose up to 48 hours after administration of study drug</time_frame>
    <description>The mean QTcF value at Cmax for participants administered a single dose of 280 mg LY2886721 was reported. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Time matched mean change from baseline in QTcF = time matched plasma concentration + participant + random error.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort A: 70 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: 70 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: 280 mg LY2886721</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2886721</intervention_name>
    <arm_group_label>Cohort A: 70 mg LY2886721</arm_group_label>
    <arm_group_label>Cohort B: 70 mg LY2886721</arm_group_label>
    <arm_group_label>Cohort C: 280 mg LY2886721</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A: Placebo</arm_group_label>
    <arm_group_label>Cohort B: Placebo</arm_group_label>
    <arm_group_label>Cohort C: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy participants have a body mass index (BMI) of 19 to 32 kilograms per square
             meter (kg/m^2), inclusive, at screening. There are no restrictions on BMI in
             participants diagnosed with Alzheimer's disease.

          -  Healthy participants should not be taking any concomitant medications. For
             participants with Alzheimer's disease, concomitant medications will be determined by
             the investigator in consultation with the Lilly clinical pharmacologist on an
             individual basis.

        Cohort A:

          -  Participants are defined as otherwise healthy males or females as determined by
             medical history and physical examination, and a diagnosis of Alzheimer's disease and
             must be at least 45 years of age.

          -  Meets National Institute of Neurological and Communicative Disorders and
             Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria
             for probable Alzheimer's disease, as determined by a clinician approved by the sponsor
             or designee.

          -  Mini Mental State Examination (MMSE) score of 16 through 28 at screening.

          -  Modified Hachinski Ischemia Scale (MHIS) score of &lt;4.

          -  Capable of understanding and signing their own informed consent, in the opinion of the
             investigator, or if the participant has a Legally Authorized Representative (LAR),
             then the LAR must be capable of understanding and signing the assent form, and the
             participant may or may not sign the informed consent, as to be determined by the
             investigator.

          -  If receiving concurrent treatment with an acetylcholinesterase inhibitor (AChEI)
             and/or memantine, the participant has been on a stable dose for at least 4 weeks
             before Day 1. Dosing must remain stable throughout the study. Note: If a participant
             has recently stopped ACHEIs and/or memantine, he or she must have discontinued
             treatment for at least 4 weeks before Day 1.

        Exclusion Criteria:

          -  Have an abnormality in the 12-lead electrocardiogram (ECG).

          -  Have abnormal blood pressure.

          -  Have abnormal thyroid function as reflected by thyroid stimulating hormone (TSH)
             values outside of the normal range.

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV
             antibodies.

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody.

          -  Have had multiple episodes of head trauma, or have a history within the last 5 years
             of a serious infectious disease affecting the brain.

          -  Have chronic hepatic disease.

          -  Have evidence or history of significant active bleeding or a coagulation disorder.

          -  Cohort A: have any neurological disorders other than Alzheimer's disease.

          -  For healthy participants (Cohorts B and C) only: Use or intend to use over the-
             counter or prescription medication, including herbal medications within 14 days prior
             to dosing or during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>May 9, 2019</results_first_submitted>
  <results_first_submitted_qc>May 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2019</results_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A: 70 mg LY2886721</title>
          <description>Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="P2">
          <title>Cohort A: Placebo</title>
          <description>Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="P3">
          <title>Cohort B: 70 mg LY2886721</title>
          <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="P4">
          <title>Cohort B: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="P5">
          <title>Cohort C: 280 mg LY2886721</title>
          <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
        </group>
        <group group_id="P6">
          <title>Cohort C: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort A: 70 mg LY2886721</title>
          <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="B2">
          <title>Cohort A: Placebo</title>
          <description>Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="B3">
          <title>Cohort B: 70 mg LY2886721</title>
          <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="B4">
          <title>Cohort B: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="B5">
          <title>Cohort C: 280 mg LY2886721</title>
          <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
        </group>
        <group group_id="B6">
          <title>Cohort C: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="12.6"/>
                    <measurement group_id="B2" value="67.0" spread="18.4"/>
                    <measurement group_id="B3" value="59.3" spread="6.8"/>
                    <measurement group_id="B4" value="54.5" spread="3.5"/>
                    <measurement group_id="B5" value="29.3" spread="11.3"/>
                    <measurement group_id="B6" value="21.3" spread="0.6"/>
                    <measurement group_id="B7" value="51.8" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721</title>
        <description>AUC0-∞ following administration of a single dose of 70 or 280 mg LY2886721.</description>
        <time_frame>Predose through 96 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 and with evaluable plasma LY2886721-concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: 280 mg LY2886721</title>
            <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Plasma LY2886721</title>
          <description>AUC0-∞ following administration of a single dose of 70 or 280 mg LY2886721.</description>
          <population>Participants who received at least one dose of LY2886721 and with evaluable plasma LY2886721-concentration data.</population>
          <units>nanograms*hours/milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2800" spread="25"/>
                    <measurement group_id="O2" value="2580" spread="20"/>
                    <measurement group_id="O3" value="10500" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721</title>
        <description>Cmax following administration of a single dose of 70 or 280 mg LY2886721.</description>
        <time_frame>Predose through 96 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 and with evaluable plasma LY2886721-concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O3">
            <title>Cohort C: 280 mg LY2886721</title>
            <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of Plasma LY2886721</title>
          <description>Cmax following administration of a single dose of 70 or 280 mg LY2886721.</description>
          <population>Participants who received at least one dose of LY2886721 and with evaluable plasma LY2886721-concentration data.</population>
          <units>nanograms/milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183" spread="41"/>
                    <measurement group_id="O2" value="180" spread="17"/>
                    <measurement group_id="O3" value="888" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721</title>
        <description>AUC0-∞ following administration of a single dose of 70 mg LY2886721.</description>
        <time_frame>Predose through 36 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level and with evaluable CSF LY2886721-concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Curve Extrapolated to Infinity (AUC0-∞) of Cerebrospinal Fluid (CSF) LY2886721</title>
          <description>AUC0-∞ following administration of a single dose of 70 mg LY2886721.</description>
          <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level and with evaluable CSF LY2886721-concentration data.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="458" spread="16"/>
                    <measurement group_id="O2" value="410" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721</title>
        <description>Cmax following administration of a single dose of 70 mg LY2886721.</description>
        <time_frame>Predose through 36 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level and with evaluable CSF LY2886721-concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of CSF LY2886721</title>
          <description>Cmax following administration of a single dose of 70 mg LY2886721.</description>
          <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level and with evaluable CSF LY2886721-concentration data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="18"/>
                    <measurement group_id="O2" value="24.4" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40</title>
        <description>Plasma concentration of Aβ1-40 was summarized based on lowest observed concentration (Cnadir).</description>
        <time_frame>Predose, up to 96 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 or placebo and had evaluable plasma Aβ 1-40 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Placebo</title>
            <description>Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
          </group>
          <group group_id="O3">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O4">
            <title>Cohort C: 280 mg LY2886721</title>
            <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
          </group>
          <group group_id="O5">
            <title>Cohorts B and C: Placebo</title>
            <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacodynamics (PD): Cnadir of Plasma Amyloid β (Aβ)1-40</title>
          <description>Plasma concentration of Aβ1-40 was summarized based on lowest observed concentration (Cnadir).</description>
          <population>Participants who received at least one dose of LY2886721 or placebo and had evaluable plasma Aβ 1-40 data.</population>
          <units>picograms/milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="35.2"/>
                    <measurement group_id="O2" value="140" spread="NA">Geometric Coefficient of Variation not reported since n &lt;3.</measurement>
                    <measurement group_id="O3" value="19.5" spread="11.9"/>
                    <measurement group_id="O4" value="11.0" spread="42.2"/>
                    <measurement group_id="O5" value="162" spread="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PD: Cnadir of CSF Aβ 1-40</title>
        <description>Plasma concentration of Aβ1-40 was summarized based on Cnadir following administration of a single dose of 70 mg LY2886721 or a single dose of LY2886721-matching placebo.</description>
        <time_frame>Predose up to 36 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level or placebo and had evaluable CSF Aβ 1-40 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A: 70 mg LY2886721</title>
            <description>Participants with Alzheimer's received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O2">
            <title>Cohort A: Placebo</title>
            <description>Participants with Alzheimer's received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
          </group>
          <group group_id="O3">
            <title>Cohort B: 70 mg LY2886721</title>
            <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
          </group>
          <group group_id="O4">
            <title>Cohort B: Placebo</title>
            <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
          </group>
        </group_list>
        <measure>
          <title>PD: Cnadir of CSF Aβ 1-40</title>
          <description>Plasma concentration of Aβ1-40 was summarized based on Cnadir following administration of a single dose of 70 mg LY2886721 or a single dose of LY2886721-matching placebo.</description>
          <population>Participants who received at least one dose of LY2886721 at the 70-mg dose level or placebo and had evaluable CSF Aβ 1-40 data.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7600" spread="30.7"/>
                    <measurement group_id="O2" value="19500" spread="NA">Geometric Coefficient of Variation not reported since n &lt;3.</measurement>
                    <measurement group_id="O3" value="4480" spread="110"/>
                    <measurement group_id="O4" value="12500" spread="NA">Geometric Coefficient of Variation not reported since n &lt;3.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort C: Mean QTcF Value at Cmax</title>
        <description>The mean QTcF value at Cmax for participants administered a single dose of 280 mg LY2886721 was reported. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Time matched mean change from baseline in QTcF = time matched plasma concentration + participant + random error.</description>
        <time_frame>Predose up to 48 hours after administration of study drug</time_frame>
        <population>Participants who received at least one dose of LY2886721 at the 280-mg dose level and with evaluable mean QTcF data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort C: 280 mg LY2886721</title>
            <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort C: Mean QTcF Value at Cmax</title>
          <description>The mean QTcF value at Cmax for participants administered a single dose of 280 mg LY2886721 was reported. The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. Time matched mean change from baseline in QTcF = time matched plasma concentration + participant + random error.</description>
          <population>Participants who received at least one dose of LY2886721 at the 280-mg dose level and with evaluable mean QTcF data.</population>
          <units>milliseconds (ms)</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" lower_limit="23.4" upper_limit="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort A: 70 mg LY2886721</title>
          <description>Participants with Alzheimer's disease received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="E2">
          <title>Cohort A: Placebo</title>
          <description>Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="E3">
          <title>Cohort B: 70 mg LY2886721</title>
          <description>Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.</description>
        </group>
        <group group_id="E4">
          <title>Cohort B: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).</description>
        </group>
        <group group_id="E5">
          <title>Cohort C: 280 mg LY2886721</title>
          <description>Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.</description>
        </group>
        <group group_id="E6">
          <title>Cohort C: Placebo</title>
          <description>Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Red blood cells csf positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

